CICLESONIDE AEROSOL,ORAL
Clinical Criteria Summary
Indications & Clinical Context
- Recommended for conversion during mometasone inhaler (Asmanex) shortage due to favorable pricing.
- Dose comparison table explicitly provided for asthma.
- Clinically used as add-on therapy to bronchodilators for COPD, though not FDA-approved for COPD.
Dosing & Administration
- Frequency of administration: Twice daily.
- Total daily dose categories (based on product labeling):
- Low: ≤160 mcg
- Medium: >160-320 mcg
- High: >320 mcg
Strengths & Formulation
- Ciclesonide HFA MDI (Alvesco) available in 80 mcg and 160 mcg strengths.
Clinical Considerations & Monitoring
- Consider disease control and severity when switching.
- Monitor patient response and adjust dose as appropriate.
- Refer to product package insert for further dosing information.
- Table provides suggested total daily doses based on product labeling, not equivalence or potency equivalence.